Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.

Ulrich FS, Frost Nielsen M, Napoli N, Burden AM

The Lancet regional health. Europe8 Jun 2026

PMID42294355PMCIDPMC13262276DOI10.1016/j.lanepe.2026.101738PepBankPUB-42294355

Summary

BackgroundThe SUSTAIN-7 trial demonstrated greater HbA1c and bodyweight reductions with once-weekly semaglutide versus dulaglutide in type 2 diabetes, but strict eligibility criteria limit external validity. We evaluated the comparative real-world effectiveness and safety of these agents in UK primary care.MethodsUsing the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023. Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting. Treatment heterogeneity was assessed in the primary per-protocol analysis by SUSTAIN-7 trial-eligibility. Safety events were assessed while-on-treatment.FindingsAmong 6616 new users, 4636 (70.1%) remained on-treatment and 1980 (29.9%) discontinued early. Semaglutide new users (n = 1901) achieved greater 1-year reductions than dulaglutide new users (n = 2735) in HbA1c (estimated treatment difference [ETD] -0.22 percentage points [95% CI -0.30, -0.15]) and bodyweight (ETD -1.92 kg [95% CI -2.91, -0.93]). While semaglutide's benefits were preserved across the 87.7% (n = 4064) not meeting SUSTAIN-7 trial-eligibility (HbA1c: ETD -0.23 percentage points [95% CI -0.31, -0.15]; bodyweight: ETD -2.01 kg [95% CI -3.07, -0.95]), reductions in HbA1c and bodyweight were greater among trial-eligible individuals (12.3%; n = 572) for both agents (trial-eligible [semaglutide/dulaglutide] versus non-eligible [semaglutide/dulaglutide] individuals, HbA1c: -1.10/-1.02 versus -0.83/-0.60 percentage points; bodyweight: -5.72/-4.18 versus -5.50/-3.49 kg). Early discontinuers showed attenuated treatment effects and higher gastrointestinal event rates than those remaining on-treatment (23.5-26.1 versus 10.6-13.8 per 100 person-years).InterpretationNew users of semaglutide achieved greater reductions in HbA1c and bodyweight than new users of dulaglutide with comparable safety, with benefits preserved across SUSTAIN-7 trial-eligible and non-eligible individuals, supporting preferential use of semaglutide in UK clinical practice.FundingSwiss National Science Foundation.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In UK T2DM database analysis, semaglutide was linked to greater HbA1c reduction than dulaglutide, with ETD -0.22 percentage points.
In plain wordsDatabase analysis linked semaglutide to greater HbA1c reduction than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c at one year
Study
n = 4,636
Comparator
dulaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Estimated treatment difference in HbA1c
−0.22 percentage points
semaglutide versus dulaglutide new users, 1 year
95% CI of HbA1c ETD
−0.3 to −0.15 percentage points
semaglutide versus dulaglutide new users, 1 year
Source sentences
Summary
Semaglutide new users (n = 1901) achieved greater 1-year reductions than dulaglutide new users (n = 2735) in HbA1c (estimated treatment difference [ETD] -0.22 percentage points [95% CI -0.30, -0.15]) and bodyweight (ETD -1.92 kg [95% CI -2.91, -0.93]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435501
02HumanObservational studyEfficacy outcome
In UK T2DM database analysis, dulaglutide was linked to less HbA1c reduction than semaglutide.
In plain wordsDatabase analysis linked dulaglutide to less HbA1c reduction than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c at one year
Study
Homo sapiensn = 4,636
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
semaglutide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (Homo sapiens).
Measurements
Estimated treatment difference, semaglutide versus dulaglutide
−0.22 percentage points
HbA1c change at 1 year, semaglutide new users versus dulaglutide new users
ETD 95% CI
−0.3 to −0.15 percentage points
HbA1c change at 1 year, semaglutide versus dulaglutide
Source sentences
Summary
Semaglutide new users (n = 1901) achieved greater 1-year reductions than dulaglutide new users (n = 2735) in HbA1c (estimated treatment difference [ETD] -0.22 percentage points [95% CI -0.30, -0.15]) and bodyweight (ETD -1.92 kg [95% CI -2.91, -0.93]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435502
03HumanObservational studyEfficacy outcome
In UK T2DM database analysis, semaglutide was linked to greater bodyweight reduction than dulaglutide, with ETD -1.92 kg.
In plain wordsDatabase analysis linked semaglutide to greater weight reduction than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseBodyweight at one year
Study
n = 4,636
Comparator
dulaglutide
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Estimated treatment difference in bodyweight
−1.92 kg
semaglutide versus dulaglutide new users, 1 year
95% CI of bodyweight ETD
−2.91 to −0.93 kg
semaglutide versus dulaglutide new users, 1 year
Source sentences
Summary
Semaglutide new users (n = 1901) achieved greater 1-year reductions than dulaglutide new users (n = 2735) in HbA1c (estimated treatment difference [ETD] -0.22 percentage points [95% CI -0.30, -0.15]) and bodyweight (ETD -1.92 kg [95% CI -2.91, -0.93]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435503
04HumanObservational studyEfficacy outcome
In UK T2DM database analysis, dulaglutide was linked to less bodyweight reduction than semaglutide.
In plain wordsDatabase analysis linked dulaglutide to less weight reduction than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBodyweight at one year
Study
Homo sapiensn = 4,636
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
semaglutide
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (Homo sapiens).
Measurements
Estimated treatment difference, semaglutide versus dulaglutide
−1.92 kg
Bodyweight change at 1 year, semaglutide new users versus dulaglutide new users
ETD 95% CI
−2.91 to −0.93 kg
Bodyweight change at 1 year, semaglutide versus dulaglutide
Source sentences
Summary
Semaglutide new users (n = 1901) achieved greater 1-year reductions than dulaglutide new users (n = 2735) in HbA1c (estimated treatment difference [ETD] -0.22 percentage points [95% CI -0.30, -0.15]) and bodyweight (ETD -1.92 kg [95% CI -2.91, -0.93]).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435504
05HumanObservational studyEfficacy outcome
In trial-ineligible UK T2DM patients, database analysis linked semaglutide to greater HbA1c reduction than dulaglutide, with ETD -0.23 percentage points.
In plain wordsIn the trial-ineligible database subgroup, analysis linked semaglutide to greater HbA1c reduction than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseTrial-ineligible HbA1c
Study
n = 4,064
Comparator
dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Estimated treatment difference in HbA1c
−0.23 percentage points
semaglutide versus dulaglutide, SUSTAIN-7 non-eligible
95% CI of HbA1c ETD
−0.31 to −0.15 percentage points
semaglutide versus dulaglutide, SUSTAIN-7 non-eligible
Source sentences
Summary
While semaglutide's benefits were preserved across the 87.7% (n = 4064) not meeting SUSTAIN-7 trial-eligibility (HbA1c: ETD -0.23 percentage points [95% CI -0.31, -0.15]; bodyweight: ETD -2.01 kg [95% CI -3.07, -0.95])
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435505
06HumanObservational studyEfficacy outcome
In trial-ineligible UK T2DM patients, database analysis linked dulaglutide to less HbA1c reduction than semaglutide.
In plain wordsIn the trial-ineligible database subgroup, analysis linked dulaglutide to less HbA1c reduction than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTrial-ineligible HbA1c
Study
Homo sapiensn = 4,064
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
semaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (Homo sapiens).
Measurements
Estimated treatment difference, semaglutide versus dulaglutide
−0.23 percentage points
HbA1c change, trial-ineligible individuals
ETD 95% CI
−0.31 to −0.15 percentage points
HbA1c change, trial-ineligible individuals, semaglutide versus dulaglutide
Source sentences
Summary
While semaglutide's benefits were preserved across the 87.7% (n = 4064) not meeting SUSTAIN-7 trial-eligibility (HbA1c: ETD -0.23 percentage points [95% CI -0.31, -0.15]; bodyweight: ETD -2.01 kg [95% CI -3.07, -0.95])
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435506
07HumanObservational studyEfficacy outcome
In trial-ineligible UK T2DM patients, database analysis linked semaglutide to greater weight reduction than dulaglutide, with ETD -2.01 kg.
In plain wordsIn the trial-ineligible database subgroup, analysis linked semaglutide to greater weight reduction than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseTrial-ineligible bodyweight
Study
n = 4,064
Comparator
dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Estimated treatment difference in bodyweight
−2.01 kg
semaglutide versus dulaglutide, SUSTAIN-7 non-eligible
95% CI of bodyweight ETD
−3.07 to −0.95 kg
semaglutide versus dulaglutide, SUSTAIN-7 non-eligible
Source sentences
Summary
While semaglutide's benefits were preserved across the 87.7% (n = 4064) not meeting SUSTAIN-7 trial-eligibility (HbA1c: ETD -0.23 percentage points [95% CI -0.31, -0.15]; bodyweight: ETD -2.01 kg [95% CI -3.07, -0.95])
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435507
08HumanObservational studyEfficacy outcome
In trial-ineligible UK T2DM patients, database analysis linked dulaglutide to less weight reduction than semaglutide.
In plain wordsIn the trial-ineligible database subgroup, analysis linked dulaglutide to less weight reduction than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTrial-ineligible bodyweight
Study
Homo sapiensn = 4,064
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (Homo sapiens).
Measurements
Estimated treatment difference, semaglutide versus dulaglutide
−2.01 kg
Bodyweight change, trial-ineligible individuals
ETD 95% CI
−3.07 to −0.95 kg
Bodyweight change, trial-ineligible individuals, semaglutide versus dulaglutide
Source sentences
Summary
While semaglutide's benefits were preserved across the 87.7% (n = 4064) not meeting SUSTAIN-7 trial-eligibility (HbA1c: ETD -0.23 percentage points [95% CI -0.31, -0.15]; bodyweight: ETD -2.01 kg [95% CI -3.07, -0.95])
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
Show in the study text Report a problemFND-4229435508

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the UK database cohort including semaglutide, early discontinuers had higher gastrointestinal event rates than those remaining on-treatment.
In plain wordsDatabase analysis linked early discontinuation to more gastrointestinal events than continued treatment in the cohort including semaglutide.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal events by discontinuation
Study
n = 6,616
Comparator
remaining on-treatment
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Gastrointestinal event rate
23.5 to 26.1 per 100 person-years
early discontinuers, semaglutide and dulaglutide cohorts
Gastrointestinal event rate
10.6 to 13.8 per 100 person-years
remaining on-treatment, semaglutide and dulaglutide cohorts
Source sentences
Summary
Early discontinuers showed attenuated treatment effects and higher gastrointestinal event rates than those remaining on-treatment (23.5-26.1 versus 10.6-13.8 per 100 person-years).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4229435515
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In UK T2DM database analysis, trial-eligible semaglutide users had greater HbA1c reductions than trial-ineligible users.
In plain wordsDatabase analysis linked trial eligibility to greater HbA1c reduction in semaglutide records than ineligible records.
Peptide
Semaglutide
Outcome
DecreaseHbA1c by trial eligibility
Study
n: not reported in source
Comparator
trial-ineligible semaglutide users
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.1 percentage points
semaglutide, trial-eligible
HbA1c change
−0.83 percentage points
semaglutide, trial-ineligible
Source sentences
Summary
reductions in HbA1c and bodyweight were greater among trial-eligible individuals (12.3%; n = 572) for both agents (trial-eligible [semaglutide/dulaglutide] versus non-eligible [semaglutide/dulaglutide] individuals, HbA1c: -1.10/-1.02 versus -0.83/-0.60 percentage points; bodyweight: -5.72/-4.18 versus -5.50/-3.49 kg)
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4229435509
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In UK T2DM database analysis, trial-eligible dulaglutide users had greater HbA1c reductions than trial-ineligible users.
In plain wordsDatabase analysis linked trial eligibility to greater HbA1c reduction in dulaglutide records than ineligible records.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c by trial eligibility
Study
Homo sapiensn: not reported in source
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
trial-ineligible dulaglutide users
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.02 percentage points
dulaglutide, trial-eligible individuals
HbA1c change
−0.6 percentage points
dulaglutide, trial-ineligible individuals
Source sentences
Summary
reductions in HbA1c and bodyweight were greater among trial-eligible individuals (12.3%; n = 572) for both agents (trial-eligible [semaglutide/dulaglutide] versus non-eligible [semaglutide/dulaglutide] individuals, HbA1c: -1.10/-1.02 versus -0.83/-0.60 percentage points;
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4229435510
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In UK T2DM database analysis, trial-eligible semaglutide users had greater weight reductions than trial-ineligible users.
In plain wordsDatabase analysis linked trial eligibility to greater weight reduction in semaglutide records than ineligible records.
Peptide
Semaglutide
Outcome
DecreaseBodyweight by trial eligibility
Study
n: not reported in source
Comparator
trial-ineligible semaglutide users
Outcome group
Body weight · Metabolic and weight
Measurements
Bodyweight change
−5.72 kg
semaglutide, trial-eligible
Bodyweight change
−5.5 kg
semaglutide, trial-ineligible
Source sentences
Summary
reductions in HbA1c and bodyweight were greater among trial-eligible individuals (12.3%; n = 572) for both agents (trial-eligible [semaglutide/dulaglutide] versus non-eligible [semaglutide/dulaglutide] individuals, HbA1c: -1.10/-1.02 versus -0.83/-0.60 percentage points; bodyweight: -5.72/-4.18 versus -5.50/-3.49 kg)
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4229435511
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In UK T2DM database analysis, trial-eligible dulaglutide users had greater weight reductions than trial-ineligible users.
In plain wordsDatabase analysis linked trial eligibility to greater weight reduction in dulaglutide records than ineligible records.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBodyweight by trial eligibility
Study
Homo sapiensn: not reported in source
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
trial-ineligible dulaglutide users
Outcome group
Body weight · Metabolic and weight
Measurements
Bodyweight change
−4.18 kg
dulaglutide, trial-eligible individuals
Bodyweight change
−3.49 kg
dulaglutide, trial-ineligible individuals
Source sentences
Summary
reductions in HbA1c and bodyweight were greater among trial-eligible individuals (12.3%; n = 572) for both agents
3 context sentences(design, population, supporting numbers)
Summary · context
bodyweight: -5.72/-4.18 versus -5.50/-3.49 kg).
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4229435512
14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In the UK database cohort including dulaglutide, early discontinuers had higher gastrointestinal event rates than those remaining on-treatment.
In plain wordsDatabase analysis linked early discontinuation to more gastrointestinal events than continued treatment in the cohort including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGastrointestinal events by discontinuation
Study
Homo sapiensn: not reported in source
Adults with type 2 diabetes initiating semaglutide or dulaglutide in UK primary care records
Comparator
remaining on-treatment
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Gastrointestinal event rate
23.5 to 26.1 per 100 person-years
early discontinuers, semaglutide and dulaglutide cohorts
Gastrointestinal event rate
10.6 to 13.8 per 100 person-years
remaining on-treatment, semaglutide and dulaglutide cohorts
Source sentences
Summary
Early discontinuers showed attenuated treatment effects and higher gastrointestinal event rates than those remaining on-treatment (23.5-26.1 versus 10.6-13.8 per 100 person-years).
2 context sentences(design, population, supporting numbers)
Summary · context
Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating semaglutide or dulaglutide between 01-Jan-2019 and 01-Dec-2022, followed through 30-Jun-2023.
Summary · context
Co-primary outcomes were 1-year changes in HbA1c and bodyweight, estimated using a new-user, active-comparator cohort design with marginal structural models and inverse probability of treatment weighting.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4229435516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.